Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to ...
EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...
Clinical Trials Arena on MSN
Clarametyx completes enrolment in cystic fibrosis trial
Clarametyx has concluded subject enrolment in its Phase Ib/IIa study of CMTX-101, an immune-enhancing antibody therapy being ...
More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim ...
The FDA granted approval to nerandomilast, now Jascayd, for treating adults with idiopathic pulmonary fibrosis, marking the ...
Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.
The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim Jascayd (nerandomilast) tablets to treat ...
Jascayd targets the enzyme PDE4B, which plays a role in the inflammatory process. The new therapy is able to affect both ...
The FDA has approved Boehringer Ingelheim's nerandomilast as a treatment for idiopathic pulmonary fibrosis (IPF), giving the ...
Derek Hill’s parents were told he might not reach his 18th birthday, but he’s still here at 28, helping coach Keller Central ...
Two newly approved medications expand options beyond lifestyle modifications for metabolic dysfunction-associated steatotic ...
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback